keyword
MENU ▼
Read by QxMD icon Read
search

edss

keyword
https://www.readbyqxmd.com/read/28088313/q-space-myelin-map-imaging-for-longitudinal-analysis-of-demyelination-and-remyelination-in-multiple-sclerosis-patients-treated-with-fingolimod-a-preliminary-study
#1
Mariko Tanikawa, Jin Nakahara, Junichi Hata, Shigeaki Suzuki, Kanehiro Fujiyoshi, Hirokazu Fujiwara, Suketaka Momoshima, Masahiro Jinzaki, Masaya Nakamura, Hideyuki Okano, Shinichi Takahashi, Norihiro Suzuki
BACKGROUND: Fingolimod (FTY) is an oral sphingosine-1-phosphate receptor modulator that reduces relapse and slows brain atrophy in multiple sclerosis (MS) patients. In addition, FTY has been shown to enhance remyelination in certain animal models. OBJECTIVE: To analyze feasibility of a novel q-space Myelin Map imaging to monitor demyelination and remyelination under FTY treatment in MS patients. METHODS: Treatment outcomes of 24 consecutive MS patients treated with FTY were analyzed...
January 5, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28086828/subjective-and-objective-assessment-of-physical-activity-in-multiple-sclerosis-and-their-relation-to-health-related-quality-of-life
#2
Theresa Krüger, Janina R Behrens, Anuschka Grobelny, Karen Otte, Sebastian Mansow-Model, Bastian Kayser, Judith Bellmann-Strobl, Alexander U Brandt, Friedemann Paul, Tanja Schmitz-Hübsch
BACKGROUND: Physical activity (PA) is frequently restricted in people with multiple sclerosis (PwMS) and aiming to enhance PA is considered beneficial in this population. We here aimed to explore two standard methods (subjective plus objective) to assess PA reduction in PwMS and to describe the relation of PA to health-related quality of life (hrQoL). METHODS: PA was objectively measured over a 7-day period in 26 PwMS (EDSS 1.5-6.0) and 30 matched healthy controls (HC) using SenseWear mini® armband (SWAmini) and reported as step count, mean total and activity related energy expenditure (EE) as well as time spent in PA of different intensities...
January 13, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28081190/inflammatory-activity-on-natalizumab-predicts-short-term-but-not-long-term-disability-in-multiple-sclerosis
#3
Joel Raffel, Arie R Gafson, Samer Dahdaleh, Omar Malik, Brynmor Jones, Richard Nicholas
BACKGROUND: In people with multiple sclerosis treated with interferon-beta or glatiramer acetate, new MRI lesions and relapses during the first year of treatment predict a poor prognosis. OBJECTIVE: To study this association in those receiving natalizumab. METHODS: Data were collected on relapses, new MRI activity, and Modified Rio Score after initiation of natalizumab in an observational cohort of 161 patients with high baseline disability...
2017: PloS One
https://www.readbyqxmd.com/read/28080255/assessing-long-term-prognosis-improvement-as-a-consequence-of-treatment-pattern-changes-in-ms
#4
Ruggero Capra, Cinzia Cordioli, Sarah Rasia, Fabio Gallo, Alessio Signori, Maria Pia Sormani
OBJECTIVE: To assess whether the age at which multiple sclerosis (MS) patients reach Expanded Disability Status Scale (EDSS) milestones changed as long as new drugs for the treatment of MS became available. METHODS: We evaluated the long-term impact of therapies on disability progression assessing whether there is a detectable delay in the age at which patients reached EDSS milestones in more recent years. We used data collected over more than 30 years in the Center of Brescia, Italy...
January 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28079804/aquaporin-4-positive-neuromyelitis-optica-spectrum-disorders-secondary-to-thrombopenic-purpura-a-case-report
#5
Ying Wang, Qiaoyun Gong, Mingqin Zhu, Chao Lu, Li Sun, Jiachun Feng, Hongliang Zhang
RATIONALE: Neuromyelitis optica spectrum disorders (NMOSD) is considered as an immune-mediated disorder in the central nervous system (CNS). Numerous autoimmune diseases are frequently complicated with NMOSD and distinct clinical characteristics are noted in NMOSD patients with other autoimmune diseases. However, to our best knowledge, co-occurrence of NMOSD and thrombopenic purpura is rarely identified. PATIENT CONCERNS: We presented a rare case of a 72-year-old female with 6-year history of thrombopenic purpura, and 1-month history of blurred vision as well as chest zonethesia...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28078563/changes-in-first-line-injectable-disease-modifying-therapy-for-multiple-sclerosis-predictors-of-non-adherence-switching-discontinuation-and-interruption-of-drugs
#6
Luca Degli Esposti, Carlo Piccinni, Diego Sangiorgi, Valentina Perrone, Lucia Aledda, Maria Giovanna Marrosu, Fabio Lombardo
This study was aimed to describe changes of Disease-Modifying Treatments (DMT) in an Italian cohort of patients with multiple sclerosis (MS) and to identify predictors of therapeutic modifications. Patients with MS and treated with the first-line injectable DMT (interferons-IFNs or glatiramer) between 1/7/2009 and 31/10/2012 were selected from administrative databases of the MS Center of Cagliari (Sardinia, Italy). Socio-demographic, therapeutic, and clinical information was collected in the 6 months preceding the index date...
January 11, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/28070886/spinal-cord-atrophy-in-anterior-posterior-direction-reflects-impairment-in-multiple-sclerosis
#7
H Lundell, O Svolgaard, A-M Dogonowski, J Romme Christensen, F Selleberg, P Soelberg Sørensen, M Blinkenberg, H R Siebner, E Garde
OBJECTIVE: To investigate how atrophy is distributed over the cross section of the upper cervical spinal cord and how this relates to functional impairment in multiple sclerosis (MS). METHODS: We analysed the structural brain MRI scans of 54 patients with relapsing-remitting MS (n=22), primary progressive MS (n=9), secondary progressive MS (n=23) and 23 age- and sex-matched healthy controls. We measured the cross-sectional area (CSA), left-right width (LRW) and anterior-posterior width (APW) of the spinal cord at the segmental level C2...
January 10, 2017: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/28069073/quantification-of-postural-stability-in-minimally-disabled-multiple-sclerosis-patients-by-means-of-dynamic-posturography-an-observational-study
#8
Lucia Grassi, Stefano Rossi, Valeria Studer, Gessica Vasco, Caterina Motta, Fabrizio Patanè, Enrico Castelli, Silvia Rossi, Paolo Cappa
BACKGROUND: Multiple Sclerosis (MS) is a widespread progressive neurologic disease with consequent impairments in daily activities. Disorders of balance are frequent and equilibrium tests are potentially useful to quantify disability and to verify treatment effectiveness. The fair sensitivity of the widely used not-perturbed tests to detect balance disturbances in MS patients have prompted the development of mechatronic systems capable to impose known equilibrium perturbations, in order to challenge the balance control and, consequently, to better assess the level of impairment...
January 10, 2017: Journal of Neuroengineering and Rehabilitation
https://www.readbyqxmd.com/read/28058965/clinical-characteristics-of-late-onset-neuromyelitis-optica-spectrum-disorder-a-multicenter-retrospective-study-in-korea
#9
Jin Myoung Seok, Hye-Jin Cho, Suk-Won Ahn, Eun Bin Cho, Min Su Park, In-Soo Joo, Ha Young Shin, Sun-Young Kim, Byung-Jo Kim, Jong Kuk Kim, Joong-Yang Cho, So-Young Huh, Ohyun Kwon, Kwang-Ho Lee, Byoung Joon Kim, Ju-Hong Min
BACKGROUND: There are currently few studies regarding late-onset neuromyelitis optica spectrum disorder (LO-NMOSD). OBJECTIVE: We aimed to describe the characteristic features of patients with LO-NMOSD in Korea. METHODS: Anti-aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder (NMOSD) from nine tertiary hospitals were reviewed retrospectively. The patients were divided into two groups based on age of onset: LO-NMOSD (⩾50 years of age at onset) versus early-onset neuromyelitis optica spectrum disorder (EO-NMOSD) (<50 years of age at onset)...
January 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28056103/healthcare-costs-for-treating-relapsing-multiple-sclerosis-and-the-risk-of-progression-a-retrospective-italian-cohort-study-from-2001-to-2015
#10
Marcello Moccia, Raffaele Palladino, Roberta Lanzillo, Antonio Carotenuto, Cinzia Valeria Russo, Maria Triassi, Vincenzo Brescia Morra
BACKGROUND: Disease modifying treatments (DMTs) are the main responsible for direct medical costs in multiple sclerosis (MS). The current investigation aims at evaluating possible associations between healthcare costs for treating relapsing remitting MS (RRMS) and disease evolution. METHODS: The present cohort study retrospectively included 544 newly diagnosed RRMS patients, prospectively followed up for 10.1±3.3 years. Costs for DMT administration and management were calculated for each year of observation...
2017: PloS One
https://www.readbyqxmd.com/read/28054826/experience-with-fampridine-in-clinical-practice-analysis-of-a-possible-marker-of-clinical-response
#11
Miriam Álvarez Payero, Candelas Valeiras Muñoz, Susana Lion Vázquez, Guadalupe Piñeiro Corrales, Delicias Muñoz García, Luciana Midaglia
PURPOSE OF THE STUDY: Approximately 85% of patients with multiple sclerosis experience reduced mobility, which negatively affects quality of life. Fampridine is the first symptomatic treatment aimed at improving gait. We analyzed effectiveness and tolerance in clinical practice. We also sought a prevalent gait pattern in responders as a potential clinical response marker. MATERIAL AND METHODS: 6-month prospective study of fampridine in patients with multiple sclerosis...
January 5, 2017: International Journal of Neuroscience
https://www.readbyqxmd.com/read/28054170/risk-factors-for-unprovoked-epileptic-seizures-in-multiple-sclerosis-a-systematic-review-and-meta-analysis
#12
REVIEW
Sara Gasparini, Edoardo Ferlazzo, Michele Ascoli, Chiara Sueri, Vittoria Cianci, Concetta Russo, Laura Rosa Pisani, Pasquale Striano, Maurizio Elia, Ettore Beghi, Carmela Colica, Umberto Aguglia
The role of different factors in influencing the risk of seizures during multiple sclerosis (MS) is not known. To perform a systematic review and meta-analysis of risk factors for epilepsy during MS. Pubmed, Google scholar, and Scopus databases were searched. Articles published in English (1986-2016) were included. Nine studies were included (3 retrospective cohort and 6 case-control) enrolling 2845 MS patients (217 with epilepsy; 7.6%). MS patients with epilepsy had a younger age at onset compared to MS patients without seizures (difference in means = -5...
January 4, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/28052465/respiratory-impairment-in-multiple-sclerosis-a-study-of-respiratory-function-in-wheelchair-bound-patients
#13
J Levy, D Bensmail, A Brotier-Chomienne, S Butel, C Joussain, C Hugeron, H Prigent
BACKGROUND AND PURPOSE: Respiratory disorders are a major cause of morbidity and mortality in multiple sclerosis (MS). Mainly reported in walking patients, they are poorly explored when walking is severely impaired. To characterize respiratory impairment in patients with advanced MS. METHODS: From 2012 to 2015, patients with MS with an Expanded Disability Status Scale (EDSS) score of ≥7 who were referred for functional and rehabilitation evaluation underwent pulmonary function tests to study lung volumes, cough efficacy and respiratory muscle pressures...
January 3, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28045953/double-blind-controlled-randomized-trial-of-cyclophosphamide-versus-methylprednisolone-in-secondary-progressive-multiple-sclerosis
#14
Bruno Brochet, Mathilde S A Deloire, Paul Perez, Timothé Loock, Louise Baschet, Marc Debouverie, Sophie Pittion, Jean-Christophe Ouallet, Pierre Clavelou, Jérôme de Sèze, Nicolas Collongues, Patrick Vermersch, Hélène Zéphir, Giovanni Castelnovo, Pierre Labauge, Christine Lebrun, Mikael Cohen, Aurélie Ruet
BACKGROUND: Therapeutic options are limited in secondary progressive multiple sclerosis (SPMS). Open-label studies suggested efficacy of monthly IV cyclophosphamide (CPM) without induction for delaying progression but no randomized trial was conducted so far. OBJECTIVE: To compare CPM to methylprednisolone (MP) in SPMS. METHODS: Randomized, double-blind clinical trial on two parallel groups. Patient with SPMS, with a documented worsening of the Expanded Disability Status Scale (EDSS) score during the last year and an EDSS score between 4·0 and 6·5 were recruited and received one intravenous infusion of treatment (CPM: 750 mg /m2 body surface area-MP: 1g) every four weeks for one year, and every eight weeks for the second year...
2017: PloS One
https://www.readbyqxmd.com/read/28039317/subcutaneous-interferon-%C3%AE-1a-in-the-treatment-of-clinically-isolated-syndromes-3-year-and-5-year-results-of-the-phase-iii-dosing-frequency-blind-multicentre-reflexion-study
#15
Giancarlo Comi, Nicola De Stefano, Mark S Freedman, Frederik Barkhof, Bernard M J Uitdehaag, Marlieke de Vos, Kurt Marhardt, Liang Chen, Delphine Issard, Ludwig Kappos
OBJECTIVE: Early treatment following a first clinical demyelinating event (FCDE) delays further disease activity in patients with multiple sclerosis (MS). This study determined the effects of early versus delayed treatment (DT) with subcutaneous interferon (sc IFN) β-1a 44 μg in patients with an FCDE up to 60 months postrandomisation. METHODS: Patients who completed the 24-month double-blind REFLEX (REbif FLEXible dosing in early MS) study entered an extension (REFLEXION, REbif FLEXible dosing in early MS extensION): patients initially randomised to sc IFN β-1a and not reaching clinically definite MS (clinically definite MS, CDMS (second attack or sustained Expanded Disability Status Scale (EDSS) score increase)) continued original treatment (three times weekly (tiw) or once weekly (qw)); placebo patients switched to tiw (DT); patients with CDMS switched to tiw...
December 30, 2016: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28038775/spinal-cord-lesions-in-children-and-adolescents-with-multiple-sclerosis-magnetic-resonance-imaging
#16
Joanna Dębska, Katarzyna Kotulska-Józwiak, Piotr Pawliszak, Małgorzata Bilska, Dariusz Chmielewski, Iwona Puzio, Elżbieta Jurkiewicz
PURPOSE: The purpose of our study was to determine the prevalence of spinal cord lesions revealed by magnetic resonance (MR) imaging in children and adolescents with clinically definite multiple sclerosis (MS). MATERIAL AND METHODS: We retrospectively evaluated the spinal cord magnetic resonance examinations in a group of MS patients consisting of 58 children (37 girls and 21 boys) aged from 7 to 17.8 years (mean 13.7 years). All children met the criteria of clinically definite MS and had typical MS lesions revealed in the brain imaging...
December 14, 2016: Neurologia i Neurochirurgia Polska
https://www.readbyqxmd.com/read/28029270/intervening-to-reduce-the-risk-of-future-disability-from-multiple-sclerosis-are-we-there-yet
#17
Maurice Dahdaleh, Raed Alroughani, Mohammed Aljumah, Abdulrahman AlTahan, Issa Alsharoqi, Saeed A Bohlega, Abdulkader Daif, Dirk Deleu, Jihad Inshasi, Rana Karabudak, Mohammed A Sahraian, Karim Taha, Bassem I Yammout, Magd Zakaria
Disease-modifying therapies (DMTs) delay or may prevent the progression of patients with high-risk clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (MS), and from relapsing-remitting MS to secondary progressive MS. Current evidence on the effects of DMT on disability in MS is supported by the use of the Expanded Disability Status Scale (EDSS), which is dominated by ambulation, and usually used as a secondary outcome measure. Less is known about the long-term effects of DMTs on other aspects of functional status, particularly cognition, which is a key determinant of ability to work...
December 28, 2016: International Journal of Neuroscience
https://www.readbyqxmd.com/read/28027680/comparative-effectiveness-of-interferons-in-relapsing-remitting-multiple-sclerosis-a-meta-analysis-of-real-world-studies
#18
Thomas R Einarson, Basil G Bereza, Márcio Machado
BACKGROUND: Differences between interferons have been evaluated for over 20 years. While RCT data are mainly used for assessments and strong data for causal inferences, they do not necessarily reflect everyday practice. Real-world data may provide additional information. PURPOSE: To assess the results, quality, and representativeness of observational studies directly comparing IFNs in RRMS. METHODS: Medline and Embase were searched for observational studies comparing IFN-beta-1a 30 mcg IM (Avonex), IFN-beta-1a 44 mcg SC (Rebif) and/or IFN-beta-1b 250 mcg SC (Betaseron)...
December 27, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28017256/treatment-of-neuromyelitis-optica-and-neuromyelitis-optica-spectrum-disorders-with-rituximab-using-a-maintenance-treatment-regimen-and-close-cd19-b-cell-monitoring-a-six-year-follow-up
#19
M E Evangelopoulos, E Andreadou, G Koutsis, V Koutoulidis, M Anagnostouli, P Katsika, D S Evangelopoulos, I Evdokimidis, C Kilidireas
Neuromyelitis optinca (NMO) represents a serious demyelinating disease of the central nervous system selectively attacking the spinal cord and optic nerve. Early differential diagnosis from multiple sclerosis is of vital importance, as NMO mandates immunosuppressive and not immunomodulatory treatment. Rituximab has been recently introduced as a treatment option for NMO. However, optimal surrogate measures and treatment intervals are still unclear. Five patients (females, mean age 54±10.21years) with NMO and NMO spectrum disorders (NMOSD) were evaluated with respect to disability and relapse rate...
January 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28017209/high-dose-methotrexate-with-leucovorin-rescue-for-monumentally-severe-cns-inflammatory-syndromes
#20
Shin C Beh, Eric Kildebeck, Ram Narayan, Allen Desena, Doug Schell, Elizabeth S Rowe, Vernon Rowe, Dennis Burns, Louis Whitworth, Teresa C Frohman, Benjamin Greenberg, Elliot M Frohman
BACKGROUND: At sufficiently high doses, methotrexate (HDMTX) achieves substantial CNS penetration, whereas other tissues can be rescued from the effects of HDMTX by leucovorin rescue (LR), which does not penetrate the blood-brain barrier. OBJECTIVES: To report on the efficacy and safety of HDMTX with LR (HDMTX-LR), in the treatment of acute demyelinating inflammatory CNS syndromes refractory to conventional immunotherapy. METHODS: We performed a retrospective chart review of 12 patients treated (6 multiple sclerosis [MS], 4 neuromyelitis optica [NMO], and 2 Sjogren's syndrome myelopathy [SSM]) with HDMTX-LR after failing to improve, or exhibiting worsening following conventional immunotherapy...
January 15, 2017: Journal of the Neurological Sciences
keyword
keyword
84088
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"